研究者詳細 - 金井　弥栄

総説・解説等 - 金井　弥栄

分割表示 116 件中 101 - 116 件目／全件表示 >>

【クリニカルシークエンスと病理診断】ゲノム研究・ゲノム医療のための病理組織検体品質管理

金井弥栄

病理と臨床（(株)文光堂） 36 （ 7 ） 635 - 640 2018年07月

その他, 単著, ISSN 0287-3745

肝硬変から肝癌へ　その臨床的・病理学的背景とメカニズム　前がん段階から肝細胞がんに至るDNAメチル化異常

金井弥栄

日本病理学会会誌（(一社)日本病理学会） 107 （ 1 ） 195 - 195 2018年04月

その他, 単著, ISSN 0300-9181

肝炎ウイルス感染・アルコール多飲・脂肪肝を伴わない肝発がんのエピゲノム異常

牧内里美, 新井恵吏, 藏本純子, 田迎, 深町幸宏, 高橋順子, 平岡伸介, 吉田輝彦, 金井弥栄

日本病理学会会誌（(一社)日本病理学会） 107 （ 1 ） 369 - 369 2018年04月

その他, 共著, ISSN 0300-9181

メチローム解析に基づいた胃がん特異的DNAメチル化マーカーの探索

亀山真一, 新井恵吏, 田迎, 伊藤菜々子, 澁谷亜矢子, 谷口浩和, 吉田輝彦, 金井弥栄

日本病理学会会誌（(一社)日本病理学会） 107 （ 1 ） 518 - 518 2018年04月

その他, 共著, ISSN 0300-9181

ゲノム・エピゲノム統合解析による胃発がん分子機構の解明

楊夢ハン, 新井恵吏, 坂本裕美, 戸塚裕彦, 谷口浩和, 吉田輝彦, 金井弥栄

日本病理学会会誌（(一社)日本病理学会） 107 （ 1 ） 431 - 431 2018年04月

その他, 共著, ISSN 0300-9181

A novel diagnostic biomarker for human uterine leiomyosarcoma: PSMB9/β1i

Hayashi T., Kawano M., Sano K., Ichimura T., Gur G., Yaish P., Zharhary D., Kanai Y., Tonegawa S., Shiozawa T., Yaegashi N., Konishi I.

Chinese Clinical Oncology （Chinese Clinical Oncology） 6 （ 2 ） 1 - 3 2017年04月

ISSN 23043865

Access to Document (DOI)

The International Human Epigenome Consortium: A Blueprint for Scientific Collaboration and Discovery

Stunnenberg H.G., Abrignani S., Adams D., de Almeida M., Altucci L., Amin V., Amit I., Antonarakis S.E., Aparicio S., Arima T., Arrigoni L., Arts R., Asnafi V., Badosa M.E., Bae J.B., Bassler K., Beck S., Berkman B., Bernstein B.E., Bilenky M., Bird A., Bock C., Boehm B., Bourque G., Breeze C.E., Brors B., Bujold D., Burren O., Bussemakers M.J., Butterworth A., Campo E., Carrillo-de-Santa-Pau E., Chadwick L., Chan K.M., Chen W., Cheung T.H., Chiapperino L., Choi N.H., Chung H.R., Clarke L., Connors J.M., Cronet P., Danesh J., Dermitzakis M., Drewes G., Durek P., Dyke S., Dylag T., Eaves C.J., Ebert P., Eils R., Eils J., Ennis C.A., Enver T., Feingold E.A., Felder B., Ferguson-Smith A., Fitzgibbon J., Flicek P., Foo R.S.Y., Fraser P., Frontini M., Furlong E., Gakkhar S., Gasparoni N., Gasparoni G., Geschwind D.H., Glažar P., Graf T., Grosveld F., Guan X.Y., Guigo R., Gut I.G., Hamann A., Han B.G., Harris R.A., Heath S., Helin K., Hengstler J.G., Heravi-Moussavi A., Herrup K., Hill S., Hilton J.A., Hitz B.C., Horsthemke B., Hu M., Hwang J.Y., Ip N.Y., Ito T., Javierre B.M., Jenko S., Jenuwein T., Joly Y., Jones S.J.M., Kanai Y., Kang H.G., Karsan A., Kiemer A.K., Kim S.C., Kim B.J.

Cell （Cell） 167 （ 5 ） 1145 - 1149 2016年11月

ISSN 00928674

© 2016 Elsevier Inc. The International Human Epigenome Consortium (IHEC) coordinates the generation of a catalog of high-resolution reference epigenomes of major primary human cell types. The studies now presented (see the Cell Press IHEC web portal at http://www.cell.com/consortium/IHEC) highlight the coordinated achievements of IHEC teams to gather and interpret comprehensive epigenomic datasets to gain insights in the epigenetic control of cell states relevant for human health and disease. PaperClip

Access to Document (DOI)

Biological characterization of soft tissue sarcomas

Hayashi T., Horiuchi A., Sano K., Kanai Y., Yaegashi N., Aburatani H., Konishi I.

Annals of Translational Medicine （Annals of Translational Medicine） 3 （ 22 ） 368 2015年12月

ISSN 23055839

© Annals of Translational Medicine. All rights reserved. Soft tissue sarcomas are neoplastic malignancies that typically arise in tissues of mesenchymal origin. The identification of novel molecular mechanisms leading to mesenchymal transformation and the establishment of new therapies and diagnostic biomarker has been hampered by several critical factors. First, malignant soft tissue sarcomas are rarely observed in the clinic with fewer than 15,000 newly cases diagnosed each year in the United States. Another complicating factor is that soft tissue sarcomas are extremely heterogeneous as they arise in a multitude of tissues from many different cell lineages. The scarcity of clinical materials coupled with its inherent heterogeneity creates a challenging experimental environment for clinicians and scientists. Faced with these challenges, there has been extremely limited advancement in clinical treatment options available to patients as compared to other malignant tumours. In order to glean insight into the pathobiology of soft tissue sarcomas, scientists are now using mouse models whose genomes have been specifically tailored to carry gene deletions, gene amplifications, and somatic mutations commonly observed in human soft tissue sarcomas. The use of these model organisms has been successful in increasing our knowledge and understanding of how alterations in relevant oncogenic and/or tumour suppressive signal cascades, i.e., interferon-γ (IFN-γ), tumour protein 53 (TP53) and/or retinoblastoma (RB) pathway directly impact sarcomagenesis. It is the goal of many in the physiological community that the use of several mouse models will serve as powerful in vivo tools for further understanding of sarcomagenesis and potentially identify new diagnostic biomarker and therapeutic strategies against human soft tissue sarcomas.

Access to Document (DOI)

Multilayer-omics analyses of human cancers: Exploration of biomarkers and drug targets based on the activities of the International Human Epigenome Consortium

Kanai Y., Arai E.

Frontiers in Genetics （Frontiers in Genetics） 5 （ FEB ） 1330 - 1342 2014年

ISSN 1664-8021

Epigenetic alterations consisting mainly of DNA methylation alterations and histone modification alterations are frequently observed in cancers associated with chronic inflammation and/or persistent infection with viruses or other pathogenic microorganisms, or with cigarette smoking. Accumulating evidence suggests that alterations of DNA methylation are involved even in the early and precancerous stages. On the other hand, in patients with cancers, aberrant DNA methylation is frequently associated with tumor aggressiveness and poor patient outcome. Recently, epigenome alterations have been attracting a great deal of attention from researchers who are focusing on not only cancers but also neuronal, immune and metabolic disorders. In order to accurately identify disease-specific epigenome profiles that could be potentially applicable for disease prevention, diagnosis and therapy, strict comparison with standard epigenome profiles of normal tissues is indispensable. However, epigenome mechanisms show heterogeneity among tissues and cell lineages. Therefore, it is not easy to obtain a comprehensive picture of standard epigenome profiles of normal tissues. In 2010, the International Human Epigenome Consortium (IHEC) was established to coordinate the production of reference maps of human epigenomes for key cellular states. In order to gain substantial coverage of the human epigenome, the IHEC has set an ambitious goal to decipher at least 1000 epigenomes within the next 7-10 years. We consider that pathway analysis using genes showing multilayer-omics abnormalities, including genome, epigenome, transcriptome, proteome and metabolome abnormalities, may be useful for elucidating the molecular background of pathogenesis and for exploring possible therapeutic targets for each disease. © 2014 Kanai and Arai.